Based on these studies, it would appear that dietary changes could prevent 1 in every 3,000 people treated for 1 year avoid ESKD, however the certainty in this effect was very low.
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
The Food and Drug Administration (FDA) has approved a labeling update for Vemlidy (tenofovir alafenamide; Gilead Sciences) to include dosage information regarding its use in adults with end-stage renal disease (ESRD; CrCl <15mL/min) who are receiving chronic hemodialysis.
The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.
The use of electrical stimulation devices (ESDs) to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) has announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior.
Drugs in the Pipeline
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
The FDA is considering banning electrical stimulation devices (ESDs) for aversive conditioning of patients exhibiting self-injurious behavior (SIB) and aggressive behavior.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
A new study has found that blood pressure (BP) below and above the current Eighth Joint National Committee (JNC 8) recommended targets is linked to an increased risk of renal disease and mortality.